Proactive Investors - Run By Investors For Investors

Medlab CEO presents clinical NanaBis update to medical practitioners

The company is pleased with data it has collected to date for NanaBis.
Nanabis spray bottle
Medlab also sees a regulatory pathway for NanaBis to become an approved drug

Medlab Clinical Ltd’s (ASX:MDC) CEO Dr Sean Hall last night, presented a clinical NanaBis update to medical practitioners as part of on-going medical education.

He explained several key aspects of NanaBis, which is a highly purified proprietary blend of cannabis molecules cannabidiol (CBD) and tetrahydrocannabinol (THC).

A summary was provided of five case studies from five different doctors that were treated with NanaBis™ in Australia under the government-approved Special Access Scheme (SAS).

Notably, the data shows significant improvements in quality of life inclusive of sleep and movement with reduced pain/restriction, reduction/replacement of previously prescribed medication (in particular opioids, reduction in pain severity scores, and reduction of symptoms.

READ: Medlab Clinical does deal for global distribution of NanaBis

Medlab noted that it is extremely pleased with the pooled data collected to date as well as the ongoing regulatory pathway for an approved drug.

NanaBis wins head-to-head with approved cannabis drug

Further to previously announced Stage 1 results, NanaBis™ data from that component of the trial was directly compared to published data for an ARTG approved Cannabis Drug.

The head to head comparison demonstrates a similar plasma level of THC and CBD with NanaBis being half the dose.

Similarly, the rate of absorption for NanaBis was faster.

Actively pursuing drug approval

Based on trial activity, Medlab is actively pursuing regulatory pathways for  TGA in Australia, FDA in the US and Europe’s EMA.

Medlab has a planned framework that should take NanaBis to an approved drug.

Proactive caught up with Dr Hall earlier this week for an update


Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

November 03 2018
Back Home Medical Cannabis Corp has agreed on a 24,000-kilogram three-year production and supply agreement
Strainsecure platform
June 19 2019
The company’s blockchain-based platform is designed to guarantee product quality and genetics throughout the cannabis supply chain from genome to patient
A WeedMD greenhouse
January 22 2019
WeedMD produces cannabis and cannabis oil for both the medical and adult-use markets

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use